JB/CALL/MODERNA/110/0.0333/21.03.25 | Market Closed - Swiss Exchange 16:20:00 21/06/2024 BST | ||
| 1.25 CHF | -2.34% |
|
| Current month | -20.89% | ||
| 1 month | -10.07% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 21/06/24 | 1.25 | -2.34% |
| 20/06/24 | 1.28 | +10.34% |
| 19/06/24 | 1.16 | -3.33% |
| 18/06/24 | 1.2 | -6.98% |
| 17/06/24 | 1.29 | -7.86% |
Delayed Quote Swiss Exchange
Last update June 21, 2024 at 04:20 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Bank Julius Bär |
| MRWOJB | |
| ISIN | CH1303723170 |
| Date issued | 23/11/2023 |
| Strike | 110 $ |
| Maturity | 21/03/2025 (271 Days) |
| Parity | 30 : 1 |
| Emission price | 0.4 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 2.12 CHF |
|---|---|
| Lowest since issue | 0.34 CHF |
| Spread | 0.01 CHF |
| Spread % | 0.80% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
133.4
USD
Average target price
145.9
USD
Spread / Average Target
+9.34%
- Stock Market
- Warrants
- MRWOJB Warrant
